Paola Neri
Calgary, AB, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 87 publications
Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma.
Journal: bioRxiv : the preprint server for biology
Published: December 19, 2025
The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.
Journal: Leukemia
Published: December 06, 2025
Erratum: International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 25, 2025
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma.
Journal: Nature medicine
Published: June 23, 2025
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 09, 2025
B7-H3 nanobody-based CAR T cells control multiple myeloma growth, while dual BCMA/B7-H3 CAR T cells overcome antigen escape.
Journal: Journal of hematology & oncology
Published: June 03, 2025
Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell-Redirecting Immunotherapies.
Journal: Blood cancer discovery
Published: January 07, 2025
Last Updated: 09/26/2026